• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The survival of treated hypertensive patients and their causes of death: a report from the DHSS hypertensive care computing project (DHCCP).

作者信息

Bulpitt C J, Beevers D G, Butler A, Coles E C, Hunt D, Munro-Faure A D, Newson R B, O'Riordan P W, Petrie J C, Rajagopalan B

出版信息

J Hypertens. 1986 Feb;4(1):93-9. doi: 10.1097/00004872-198602000-00015.

DOI:10.1097/00004872-198602000-00015
PMID:3958486
Abstract

A prospective study has been carried out to determine the causes of death and risk factors for survival in 4994 patients referred with a diagnosis of hypertension to hospital specialist clinics and 457 patients treated by their general practitioners for this condition. At the time of entering the prospective study, 69% of the patients were already being treated for hypertension. Four hundred and eleven patients have died, and their causes of death and death rates have been compared with the rates for the population of England and Wales. Ischaemic heart disease accounted for over one-third of the deaths and stroke for one-fifth. The death rates for these conditions were two to five times those expected for men and women aged 50-59 years and up to twice the rate expected for the age group 60-69 years. Survival in these selected patients was impaired by the following independent risk indicators: cigarette smoking, previous history of myocardial infarction or stroke, diagnosis of angina, impaired renal function and raised blood sugar. The following factors were not independent positive risk factors: smoking a pipe or cigars, obesity, a low plasma potassium and an elevated serum uric acid.

摘要

相似文献

1
The survival of treated hypertensive patients and their causes of death: a report from the DHSS hypertensive care computing project (DHCCP).
J Hypertens. 1986 Feb;4(1):93-9. doi: 10.1097/00004872-198602000-00015.
2
Risk factors for death in treated hypertensive patients. Report from the D.H.S.S. Hypertension Care Computing Project.接受治疗的高血压患者的死亡风险因素。来自卫生和社会保障部高血压护理计算机项目的报告。
Lancet. 1979 Jul 21;2(8134):134-7. doi: 10.1016/s0140-6736(79)90013-8.
3
Ischaemic heart disease, stroke and total mortality in women--results from a prospective population study in Gothenburg, Sweden.女性缺血性心脏病、中风与全因死亡率——瑞典哥德堡一项前瞻性人群研究的结果
Acta Med Scand Suppl. 1985;705:1-42. doi: 10.1111/j.0954-6820.1985.tb18928.x.
4
Optimal blood pressure control in treated hypertensive patients. Report from the Department of Health Hypertension Care Computing Project (DHCCP).高血压患者治疗中的最佳血压控制。卫生部高血压护理计算项目(DHCCP)报告。
Circulation. 1994 Jul;90(1):225-33. doi: 10.1161/01.cir.90.1.225.
5
Fifteen year survival of patients presenting with hypertension to a hospital clinic.在一家医院诊所就诊的高血压患者的15年生存率。
Postgrad Med J. 1986 May;62(727):335-40. doi: 10.1136/pgmj.62.727.335.
6
The relationship between a low treated blood pressure and IHD mortality: a report from the DHSS Hypertension Care Computing Project (DHCCP).治疗后低血压与缺血性心脏病死亡率之间的关系:卫生和社会保障部高血压护理计算机项目(DHCCP)的报告。
J Hum Hypertens. 1988 Jun;2(1):11-5.
7
Mortality in patients of the Glasgow Blood Pressure Clinic.格拉斯哥血压诊所患者的死亡率。
J Hypertens. 1986 Apr;4(2):141-56. doi: 10.1097/00004872-198604000-00003.
8
Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke.
Stroke. 1997 Mar;28(3):557-63. doi: 10.1161/01.str.28.3.557.
9
A comparison of trends of coronary heart disease mortality in Australia, USA and England and Wales with reference to three major risk factors-hypertension, cigarette smoking and diet.参照高血压、吸烟和饮食这三大主要风险因素,对澳大利亚、美国以及英格兰和威尔士的冠心病死亡率趋势进行比较。
Int J Epidemiol. 1980 Mar;9(1):65-71. doi: 10.1093/ije/9.1.65.
10
Beta adrenoceptor blockade is associated with increased survival in male but not female hypertensive patients: a report from the DHSS Hypertension Care Computing Project (DHCCP).β肾上腺素能受体阻滞剂与男性高血压患者生存率的提高相关,但与女性高血压患者无关:来自卫生与社会保障部高血压护理计算机项目(DHCCP)的报告。
J Hum Hypertens. 1988 Dec;2(4):219-27.

引用本文的文献

1
Traditional risk factors and premature acute coronary syndromes in South Eastern Europe: a multinational cohort study.东南欧的传统风险因素与早发急性冠状动脉综合征:一项多国队列研究。
Lancet Reg Health Eur. 2024 Jan 2;38:100824. doi: 10.1016/j.lanepe.2023.100824. eCollection 2024 Mar.
2
Microalbuminuria in hypertension.高血压中的微量白蛋白尿
Curr Hypertens Rep. 2003 Jun;5(3):208-14. doi: 10.1007/s11906-003-0022-0.
3
Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease.
治疗高脂血症或高血压对降低冠状动脉疾病死亡风险的影响。
CMAJ. 1999 May 18;160(10):1449-55.
4
Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.英国关于临床实践中冠心病预防的联合建议。英国心脏病学会、英国高脂血症协会、英国高血压学会,获英国糖尿病协会认可。
Heart. 1998 Dec;80 Suppl 2(Suppl 2):S1-29.
5
Selective versus nonselective beta adrenoceptor antagonists in hypertension.高血压治疗中选择性与非选择性β肾上腺素能受体拮抗剂的比较
Pharmacoeconomics. 1995 Dec;8(6):513-23. doi: 10.2165/00019053-199508060-00006.
6
Survival in treated hypertension: follow up study after two decades.高血压治疗后的生存情况:二十年随访研究
BMJ. 1998 Jul 18;317(7152):167-71. doi: 10.1136/bmj.317.7152.167.
7
ACE inhibitors and proteinuria.血管紧张素转换酶抑制剂与蛋白尿
Pharm World Sci. 1996 Dec;18(6):204-10. doi: 10.1007/BF00735961.
8
Experiences from hypertension trials. Impact of other risk factors.
Drugs. 1988;36 Suppl 3:9-20. doi: 10.2165/00003495-198800363-00005.
9
Proteinuria as a prognostic factor during long term hypertensive care.
Drugs. 1988;35 Suppl 5:48-54. doi: 10.2165/00003495-198800355-00008.
10
Risk of serious morbidity associated with hydralazine versus methyldopa treatment in hypertensive patients.高血压患者中与肼屈嗪治疗相比,甲基多巴治疗相关的严重发病风险。
Eur J Clin Pharmacol. 1991;40(4):327-31. doi: 10.1007/BF00265839.